Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15682809 | 1.00 | MAPK14 (0.59) | MAPK14ROCK1ROCK2HTR2CKDM5A | |
| SCHEMBL4575965 | 0.88 | MAPK14 (0.60) | MAPK14ROCK1ROCK2HTR2CKDM5A | |
| SCHEMBL23195276 | 0.86 | MAPK14 (0.65) | MAPK14ROCK1ROCK2HTR2CKDM5A | |
| SCHEMBL30152446 | 0.86 | MAPK14 (0.65) | MAPK14ROCK1ROCK2HTR2CKDM5A | |
| SCHEMBL13647056 | 0.85 | MAPK14 (0.63) | MAPK14ROCK1ROCK2HTR2CKDM5A | |
| SCHEMBL15682671 | 0.83 | EPHX2 (0.56) | HTR2CNAMPTPPARGPPARA | |
| SCHEMBL5724446 | 0.82 | MAPK14 (0.63) | MAPK14ROCK1ROCK2HTR2CKDM5A | |
| SCHEMBL15682810 | 0.82 | ALDH1A1 (0.63) | MMP13 | |
| SCHEMBL21981021 | 0.80 | AOC2 (0.51) | MAPK14ROCK1ROCK2GLSCNR1 | |
| SCHEMBL13853494 | 0.80 | MAPK14 (0.60) | MAPK14ROCK1ROCK2KDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713445-A2 | RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF | Versiti Blood Research Institute Foundation, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| WO-2024238942-A2 | RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF | VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| US-20230398123-A1 | METHODS TO TREAT INFLAMMATORY BOWEL DISEASE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-12-14 | — | — | US | claimed |
| EP-4208170-A1 | METHODS TO TREAT INFLAMMATORY BOWEL DISEASE | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-07-12 | — | — | EP | claimed |
| CN-116209447-A | Methods of treating inflammatory bowel disease | 上海医药集团股份有限公司 | 2023-06-02 | — | — | CN | claimed |
| WO-2022048618-A1 | METHODS TO TREAT INFLAMMATORY BOWEL DISEASE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-03-10 | — | — | WO | claimed |
| WO-2022047730-A1 | METHODS TO TREAT INFLAMMATORY BOWEL DISEASE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-03-10 | — | — | WO | claimed |
| EP-4713445-A2 | RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF | Versiti Blood Research Institute Foundation, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238942-A2 | RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF | VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20230398123-A1 | METHODS TO TREAT INFLAMMATORY BOWEL DISEASE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| EP-4208170-A1 | METHODS TO TREAT INFLAMMATORY BOWEL DISEASE | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-07-12 | — | — | EP | disclosed |
| CN-116209447-A | Methods of treating inflammatory bowel disease | 上海医药集团股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2022048618-A1 | METHODS TO TREAT INFLAMMATORY BOWEL DISEASE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022047730-A1 | METHODS TO TREAT INFLAMMATORY BOWEL DISEASE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398123-A1 | METHODS TO TREAT INFLAMMATORY BOWEL DISEASE | SLC10A2, SI, SLC10A1 | MAPK14 1649/4885ROCK1 637/4885ROCK2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.